Related Experiment Video

Updated: Dec 21, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K

The antiatherogenic function of kallistatin and its potential mechanism

Gang Wang1, Jin Zou1, Xiaohua Yu2

  • 1Department of Cardiology, The First Affiliated Hospital of University of South China, Institute of Cardiovascular Disease, Key Laboratory for Atherosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Medical Research Experiment Center, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang Medical College, University of South China, Hengyang 421001, China.

Acta Biochimica Et Biophysica Sinica
|May 13, 2020
PubMed

Insights

Kallistatin, a protein found in human serum, shows promise in combating atherosclerosis. Lower levels correlate with severe coronary artery disease, suggesting kallistatin as a potential therapeutic target.

Area of Science:

  • Cardiovascular Research
  • Biochemistry
  • Molecular Biology

Background:

  • Atherosclerosis is a primary driver of global cardiovascular disease mortality.
  • Kallistatin, a serine proteinase inhibitor, interacts with multiple receptors to regulate biological processes.
  • Reduced circulating kallistatin levels are observed in coronary artery disease patients.

Purpose of the Study:

  • To review the antiatherogenic functions of kallistatin.
  • To elucidate the mechanisms by which kallistatin impacts atherosclerosis.
  • To explore kallistatin's potential as a biomarker and therapeutic target.

Main Methods:

  • Literature review focusing on kallistatin's role in atherosclerosis.
  • Analysis of in vitro and in vivo experimental data.
  • Examination of kallistatin's interactions with its known receptors.

Main Results:

  • Kallistatin inhibits vascular inflammation, endothelial dysfunction, and improves lipid metabolism.
  • Kallistatin's signaling modulation affects angiogenesis, inflammation, and oxidative stress.
  • Decreased kallistatin levels correlate inversely with coronary artery disease severity.

Conclusions:

  • Kallistatin exhibits significant antiatherogenic properties.
  • Kallistatin's mechanisms involve modulating key biological pathways relevant to atherosclerosis.
  • Kallistatin represents a potential novel biomarker and therapeutic strategy for atherosclerosis.

Keywords:
Krüppel-like factor 4atherosclerosisinflammationkallistatin

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
261
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
647
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K